Research progress of anti-vascular endothelial growth factor in cataract surgery for diabetic retinopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

Zhang Qi , Xie Dasen ,  Li Yonghao

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China;

Corresponding author：

Li Yonghao, Email: liyhao@mail.sysu.edu.cn

Keywords：

Diabetic retinopathy; Cataract extraction; Angiogenesis inhibitors; Review

DOI：

10.3760/cma.j.cn511434-20210122-00047

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Diabetic retinopathy (DR) is a common ocular complication in diabetic patients, which is chronic and progressive and seriously impairs visual acuity. The rapid occurrence and progress of cataract in diabetic patients is also one of the important reasons for visual impairment in DR patients. Compared with non-diabetic patients, diabetic patients have higher risk of complications after cataract surgery. Studies have shown that anti-vascular endothelial growth factor (VEGF) therapy after cataract surgery can prevent the aggravation of diabetic macular edema in DR patients. However, due to the lack of systematic review of the clinical effect of anti-VEGF drugs in DR patients undergoing cataract surgery, the use of anti-VEGF drugs is relatively conservative in clinic. It is believed that with the deepening of research and the progress of clinical trials, the wide application of anti-VEGF drugs in clinical practice is expected to provide more accurate and effective treatment for DR patients in the future.

Citation： Zhang Qi, Xie Dasen, Li Yonghao. Research progress of anti-vascular endothelial growth factor in cataract surgery for diabetic retinopathy. Chinese Journal of Ocular Fundus Diseases, 2022, 38(1): 72-76. doi: 10.3760/cma.j.cn511434-20210122-00047 Copy

1.	Wong TY, Cheung CM, Larsen M, et al. Diabetic retinopathy[J/OL]. Nat Rev Dis Primers, 2016, 2: 16012[2016-03-17]. https://pubmed.ncbi.nlm.nih.gov/27159554/. DOI: 10.1038/nrdp.2016.12.
2.	Klein R, Lee KE, Gangnon RE, et al. The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy[J]. Ophthalmology, 2010, 117(1): 63-70. DOI: 10.1016/j.ophtha.2009.06.051.
3.	Simó R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy[J]. Diabetes Care, 2014, 37(4): 893-899. DOI: 10.2337/dc13-2002.
4.	Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase Ⅲ randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4): 789-801. DOI: 10.1016/j.ophtha.2011.12.039.
5.	Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J]. Ophthalmology, 2011, 118(4): 609-614. DOI: 10.1016/j.ophtha.2010.12.033.
6.	Ho AC, Scott IU, Kim SJ, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2012, 119(10): 2179-2188. DOI: 10.1016/j.ophtha.2012.07.058.
7.	Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema[J]. Ophthalmology, 2011, 118(4): 615-625. DOI: 10.1016/j.ophtha.2011.01.031.
8.	Chen CH, Liu YC, Wu PC. The combination of intravitreal bevacizumab and phacoemulsification surgery in patients with cataract and coexisting diabetic macular edema[J]. J Ocul Pharmacol Ther, 2009, 25(1): 83-89. DOI: 10.1089/jop.2008.0068.
9.	Akinci A, Muftuoglu O, Altinsoy A, et al. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract[J]. Retina, 2011, 31(4): 755-758. DOI: 10.1097/IAE.0b013e3182006da1.
10.	Miller DC, Christopher KL, Patnaik JL, et al. Posterior capsule rupture during cataract surgery in eyes receiving intravitreal anti-VEGF injections[J]. Curr Eye Res, 2021, 46(2): 179-184. DOI: 10.1080/02713683.2020.1795884.
11.	Hahn P, Yashkin AP, Sloan FA. Effect of prior anti-VEGF injections on the risk of retained lens fragments and endophthalmitis after cataract surgery in the elderly[J]. Ophthalmology, 2016, 123(2): 309-315. DOI: 10.1016/j.ophtha.2015.06.040.
12.	Klein BE, Klein R, Moss SE. Prevalence of cataracts in a population-based study of persons with diabetes mellitus[J]. Ophthalmology, 1985, 92(9): 1191-1196. DOI: 10.1016/s0161-6420(85)33877-0.
13.	Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options[J]. Endocr Rev, 2005, 26(3): 380-392. DOI: 10.1210/er.2004-0028.
14.	Chung SS, Ho EC, Lam KS, et al. Contribution of polyol pathway to diabetes-induced oxidative stress[J]. J Am Soc Nephrol, 2003, 14(8 Suppl 3): S233-236. DOI: 10.1097/01.asn.0000077408.15865.06.
15.	Pollreisz A, Schmidt-Erfurth U. Diabetic cataract-pathogenesis, epidemiology and treatment[J/OL]. J Ophthalmol, 2010, 2010: 608751[2010-06-17]. https://pubmed.ncbi.nlm.nih.gov/20634936/. DOI: 10.1155/2010/608751.
16.	Matsumoto T, Ono Y, Kuromiya A, et al. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats[J]. J Pharmacol Sci, 2008, 107(3): 340-348. DOI: 10.1254/jphs.08071fp.
17.	Kojima M, Sun L, Hata I, et al. Efficacy of alpha-lipoic acid against diabetic cataract in rat[J]. Jpn J Ophthalmol, 2007, 51(1): 10-13. DOI: 10.1007/s10384-006-0384-3.
18.	Meyer CH, Sekundo W. Nutritional supplementation to prevent cataract formation[J]. Dev Ophthalmol, 2005, 38: 103-119. DOI: 10.1159/000082771.
19.	Saxena S, Mitchell P, Rochtchina E. Five-year incidence of cataract in older persons with diabetes and pre-diabetes[J]. Ophthalmic Epidemiol, 2004, 11(4): 271-277. DOI: 10.1080/09286580490510733.
20.	Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss[J]. Eye Vis (Lond), 2015, 2: 17. DOI: 10.1186/s40662-015-0026-2.
21.	Raman R, Pal SS, Adams JS, et al. Prevalence and risk factors for cataract in diabetes: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study, report No. 17[J]. Invest Ophthalmol Vis Sci, 2010, 51(12): 6253-6261. DOI: 10.1167/iovs.10-5414.
22.	Chew EY, Benson WE, Remaley NA, et al. Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25[J]. Arch Ophthalmol, 1999, 117(12): 1600-1606. DOI: 10.1001/archopht.117.12.1600.
23.	Ostri C, Lund-Andersen H, Sander B, et al. Phacoemulsification cataract surgery in a large cohort of diabetes patients: visual acuity outcomes and prognostic factors[J]. J Cataract Refract Surg, 2011, 37(11): 2006-2012. DOI: 10.1016/j.jcrs.2011.05.030.
24.	Eriksson U, Alm A, Bjarnhall G, et al. Macular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controls[J]. Graefe's Arch Clin Exp Ophthalmol, 2011, 249(3): 349-359. DOI: 10.1007/s00417-010-1484-9.
25.	Stunf Pukl S, Vidović Valentinčič N, Urbančič M, et al. Visual acuity, retinal sensitivity, and macular thickness changes in diabetic patients without diabetic retinopathy after cataract surgery[J/OL]. J Diabetes Res, 2017, 2017: 3459156[2017-01-24]. https://pubmed.ncbi.nlm.nih.gov/28243608/. DOI: 10.1155/2017/3459156.
26.	Liu L, Herrinton LJ, Alexeeff S, et al. Visual outcomes after cataract surgery in patients with type 2 diabetes[J]. J Cataract Refract Surg, 2019, 45(4): 404-413. DOI: 10.1016/j.jcrs.2018.11.002.
27.	Zhu B, Ma Y, Lin S, et al. Vision-related quality of life and visual outcomes from cataract surgery in patients with vision-threatening diabetic retinopathy: a prospective observational study[J]. Health Qual Life Outcomes, 2017, 15(1): 175. DOI: 10.1186/s12955-017-0751-4.
28.	Yonekawa Y, Kim IK. Pseudophakic cystoid macular edema[J]. Curr Opin Ophthalmol, 2012, 23(1): 26-32. DOI: 10.1097/ICU.0b013e32834cd5f8.
29.	Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes[J]. Ophthalmology, 2016, 123(2): 316-323. DOI: 10.1016/j.ophtha.2015.10.001.
30.	Yang J, Cai L, Sun Z, et al. Risk factors for and diagnosis of pseudophakic cystoid macular edema after cataract surgery in diabetic patients[J]. J Cataract Refract Surg, 2017, 43(2): 207-214. DOI: 10.1016/j.jcrs.2016.11.047.
31.	Zaczek A, Olivestedt G, Zetterstrom C. Visual outcome after phacoemulsification and IOL implantation in diabetic patients[J]. Br J Ophthalmol, 1999, 83(9): 1036-1041. DOI: 10.1136/bjo.83.9.1036.
32.	Mittra RA, Borrillo JL, Dev S, et al. Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus[J]. Arch Ophthalmol, 2000, 118(7): 912-917.
33.	Hong T, Mitchell P, de Loryn T, et al. Development and progression of diabetic retinopathy 12 months after phacoemulsification cataract surgery[J]. Ophthalmology, 2009, 116(8): 1510-1514. DOI: 10.1016/j.ophtha.2009.03.003.
34.	Jeng CJ, Hsieh YT, Yang CM, et al. Development of diabetic retinopathy after cataract surgery[J/OL]. PLoS One, 2018, 13(8): e202347[2018-08-22]. https://pubmed.ncbi.nlm.nih.gov/30133506/. DOI: 10.1371/journal.pone.0202347.
35.	Brito PN, Rosas VM, Coentrão LM, et al. Evaluation of visual acuity, macular status, and subfoveal choroidal thickness changes after cataract surgery in eyes with diabetic retinopathy[J]. Retina, 2015, 35(2): 294-302. DOI: 10.1097/IAE.0000000000000298.
36.	Tang J, Kern TS. Inflammation in diabetic retinopathy[J]. Prog Retin Eye Res, 2011, 30(5): 343-358. DOI: 10.1016/j.preteyeres.2011.05.002.
37.	Liu Y, Luo L, He M, et al. Disorders of the blood-aqueous barrier after phacoemulsification in diabetic patients[J]. Eye (Lond), 2004, 18(9): 900-904. DOI: 10.1038/sj.eye.6701349.
38.	Grzybowski A, Kanclerz P, Huerva V, et al. Diabetes and phacoemulsification cataract surgery: difficulties, risks and potential complications[J]. J Clin Med, 2019, 8(5): 716. DOI: 10.3390/jcm8050716.
39.	Dowler JG, Hykin PG, Hamilton AM. Phacoemulsification versus extracapsular cataract extraction in patients with diabetes[J]. Ophthalmology, 2000, 107(3): 457-462. DOI: 10.1016/s0161-6420(99)00136-0.
40.	Jaffe GJ, Burton TC. Progression of nonproliferative diabetic retinopathy following cataract extraction[J]. Arch Ophthalmol, 1988, 106(6): 745-749. DOI: 10.1001/archopht.1988.01060130815029.
41.	Squirrell D, Bhola R, Bush J, et al. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes[J]. Br J Ophthalmol, 2002, 86(5): 565-571. DOI: 10.1136/bjo.86.5.565.
42.	Diabetic Retinopathy Clinical Research Network Authors/Writing Committee, Baker CW, Almukhtar T, et al. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema[J]. JAMA Ophthalmol, 2013, 131(7): 870-879. DOI: 10.1001/jamaophthalmol.2013.2313.
43.	Aiello LM. Perspectives on diabetic retinopathy[J]. Am J Ophthalmol, 2003, 136(1): 122-135. DOI: 10.1016/s0002-9394(03)00219-8.
44.	Scott IU, Danis RP, Bressler SB, et al. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema[J]. Retina, 2009, 29(5): 613-617. DOI: 10.1097/IAE.0b013e3181a2c07a.
45.	Chung J, Kim MY, Kim HS, et al. Effect of cataract surgery on the progression of diabetic retinopathy[J]. J Cataract Refract Surg, 2002, 28(4): 626-630. DOI: 10.1016/s0886-3350(01)01142-7.
46.	Krepler K, Biowski R, Schrey S, et al. Cataract surgery in patients with diabetic retinopathy: visual outcome, progression of diabetic retinopathy, and incidence of diabetic macular oedema[J]. Graefe's Arch Clin Exp Ophthalmol, 2002, 240(9): 735-738. DOI: 10.1007/s00417-002-0530-7.
47.	Chen XY, Song WJ, Cai HY, et al. Macular edema after cataract surgery in diabetic eyes evaluated by optical coherence tomography[J]. Int J Ophthalmol, 2016, 9(1): 81-85. DOI: 10.18240/ijo.2016.01.14.
48.	Dowler JG, Sehmi KS, Hykin PG, et al. The natural history of macular edema after cataract surgery in diabetes[J]. Ophthalmology, 1999, 106(4): 663-668. DOI: 10.1016/S0161-6420(99)90148-3.
49.	Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis[J]. Br J Ophthalmol, 2006, 90(6): 697-701. DOI: 10.1136/bjo.2005.087403.
50.	Dong N, Xu B, Wang B, et al. Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery[J/OL]. Biomed Res Int, 2015, 2015: 126984[2015-02-25]. https://pubmed.ncbi.nlm.nih.gov/25811020/. DOI: 10.1155/2015/ 126984.
51.	Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution[J]. Clin Ophthalmol, 2009, 3: 199-210. DOI: 10.2147/opth.s4806.
52.	Hartnett ME, Tinkham N, Paynter L, et al. Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus[J]. Am J Ophthalmol, 2009, 148(6): 895-901. DOI: 10.1016/j.ajo.2009.07.014.
53.	Wielders LHP, Schouten JSAG, Winkens B, et al. Randomized controlled European multicenter trial on the prevention of cystoid macular edema after cataract surgery in diabetics: ESCRS PREMED Study Report 2[J]. J Cataract Refract Surg, 2018, 44(7): 836-847. DOI: 10.1016/j.jcrs.2018.05.015.
54.	Fard MA, Yazdanei AA, Malihi M. Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: prospective randomized study[J]. Eur J Ophthalmol, 2011, 21(3): 276-281. DOI: 10.5301/EJO.2010.1405.
55.	Udaondo P, Garcia-Pous M, Garcia-Delpech S, et al. Prophylaxis of macular edema with intravitreal ranibizumab in patients with diabetic retinopathy after cataract surgery: a pilot study[J/OL]. J Ophthalmol, 2011, 2011: 159436[2011-06-16]. https://pubmed.ncbi.nlm.nih.gov/21772983/. DOI: 10.1155/2011/159436.
56.	Chae JB, Joe SG, Yang SJ, et al. Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy[J]. Retina, 2014, 34(1): 149-156. DOI: 10.1097/IAE.0b013e3182979b9e.
57.	Hayashi K, Igarashi C, Hirata A, et al. Changes in diabetic macular oedema after phacoemulsification surgery[J]. Eye (Lond), 2009, 23(2): 389-396. DOI: 10.1038/sj.eye.6703022.
58.	Moshfeghi AA, Shapiro H, Lemmon LA, et al. Impact of cataract surgery during treatment with ranibizumab in patients with diabetic macular edema[J]. Ophthalmol Retina, 2018, 2(2): 86-90. DOI: 10.1016/j.oret.2017.05.003.
59.	Takamura Y, Kubo E, Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery[J]. Ophthalmology, 2009, 116(6): 1151-1157. DOI: 10.1016/j.ophtha.2009.01.014.
60.	Lanzagorta-Aresti A, Palacios-Pozo E, Menezo RJ, et al. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study[J]. Retina, 2009, 29(4): 530-535. DOI: 10.1097/IAE.0b013e31819c6302.
61.	Zhao LQ, Cheng JW. A systematic review and meta-analysis of clinical outcomes of intravitreal anti-VEGF agent treatment immediately after cataract surgery for patients with diabetic retinopathy[J/OL]. J Ophthalmol, 2019, 2019: 2648267[2019-04-16]. https://pubmed.ncbi.nlm.nih.gov/31143469/. DOI: 10.1155/2019/2648267.
62.	Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10): 1608-1622. DOI: 10.1016/j.ophtha.2018.04.007.

1. Wong TY, Cheung CM, Larsen M, et al. Diabetic retinopathy[J/OL]. Nat Rev Dis Primers, 2016, 2: 16012[2016-03-17]. https://pubmed.ncbi.nlm.nih.gov/27159554/. DOI: 10.1038/nrdp.2016.12.
2. Klein R, Lee KE, Gangnon RE, et al. The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy[J]. Ophthalmology, 2010, 117(1): 63-70. DOI: 10.1016/j.ophtha.2009.06.051.
3. Simó R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy[J]. Diabetes Care, 2014, 37(4): 893-899. DOI: 10.2337/dc13-2002.
4. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase Ⅲ randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4): 789-801. DOI: 10.1016/j.ophtha.2011.12.039.
5. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J]. Ophthalmology, 2011, 118(4): 609-614. DOI: 10.1016/j.ophtha.2010.12.033.
6. Ho AC, Scott IU, Kim SJ, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2012, 119(10): 2179-2188. DOI: 10.1016/j.ophtha.2012.07.058.
7. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema[J]. Ophthalmology, 2011, 118(4): 615-625. DOI: 10.1016/j.ophtha.2011.01.031.
8. Chen CH, Liu YC, Wu PC. The combination of intravitreal bevacizumab and phacoemulsification surgery in patients with cataract and coexisting diabetic macular edema[J]. J Ocul Pharmacol Ther, 2009, 25(1): 83-89. DOI: 10.1089/jop.2008.0068.
9. Akinci A, Muftuoglu O, Altinsoy A, et al. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract[J]. Retina, 2011, 31(4): 755-758. DOI: 10.1097/IAE.0b013e3182006da1.
10. Miller DC, Christopher KL, Patnaik JL, et al. Posterior capsule rupture during cataract surgery in eyes receiving intravitreal anti-VEGF injections[J]. Curr Eye Res, 2021, 46(2): 179-184. DOI: 10.1080/02713683.2020.1795884.
11. Hahn P, Yashkin AP, Sloan FA. Effect of prior anti-VEGF injections on the risk of retained lens fragments and endophthalmitis after cataract surgery in the elderly[J]. Ophthalmology, 2016, 123(2): 309-315. DOI: 10.1016/j.ophtha.2015.06.040.
12. Klein BE, Klein R, Moss SE. Prevalence of cataracts in a population-based study of persons with diabetes mellitus[J]. Ophthalmology, 1985, 92(9): 1191-1196. DOI: 10.1016/s0161-6420(85)33877-0.
13. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options[J]. Endocr Rev, 2005, 26(3): 380-392. DOI: 10.1210/er.2004-0028.
14. Chung SS, Ho EC, Lam KS, et al. Contribution of polyol pathway to diabetes-induced oxidative stress[J]. J Am Soc Nephrol, 2003, 14(8 Suppl 3): S233-236. DOI: 10.1097/01.asn.0000077408.15865.06.
15. Pollreisz A, Schmidt-Erfurth U. Diabetic cataract-pathogenesis, epidemiology and treatment[J/OL]. J Ophthalmol, 2010, 2010: 608751[2010-06-17]. https://pubmed.ncbi.nlm.nih.gov/20634936/. DOI: 10.1155/2010/608751.
16. Matsumoto T, Ono Y, Kuromiya A, et al. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats[J]. J Pharmacol Sci, 2008, 107(3): 340-348. DOI: 10.1254/jphs.08071fp.
17. Kojima M, Sun L, Hata I, et al. Efficacy of alpha-lipoic acid against diabetic cataract in rat[J]. Jpn J Ophthalmol, 2007, 51(1): 10-13. DOI: 10.1007/s10384-006-0384-3.
18. Meyer CH, Sekundo W. Nutritional supplementation to prevent cataract formation[J]. Dev Ophthalmol, 2005, 38: 103-119. DOI: 10.1159/000082771.
19. Saxena S, Mitchell P, Rochtchina E. Five-year incidence of cataract in older persons with diabetes and pre-diabetes[J]. Ophthalmic Epidemiol, 2004, 11(4): 271-277. DOI: 10.1080/09286580490510733.
20. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss[J]. Eye Vis (Lond), 2015, 2: 17. DOI: 10.1186/s40662-015-0026-2.
21. Raman R, Pal SS, Adams JS, et al. Prevalence and risk factors for cataract in diabetes: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study, report No. 17[J]. Invest Ophthalmol Vis Sci, 2010, 51(12): 6253-6261. DOI: 10.1167/iovs.10-5414.
22. Chew EY, Benson WE, Remaley NA, et al. Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25[J]. Arch Ophthalmol, 1999, 117(12): 1600-1606. DOI: 10.1001/archopht.117.12.1600.
23. Ostri C, Lund-Andersen H, Sander B, et al. Phacoemulsification cataract surgery in a large cohort of diabetes patients: visual acuity outcomes and prognostic factors[J]. J Cataract Refract Surg, 2011, 37(11): 2006-2012. DOI: 10.1016/j.jcrs.2011.05.030.
24. Eriksson U, Alm A, Bjarnhall G, et al. Macular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controls[J]. Graefe's Arch Clin Exp Ophthalmol, 2011, 249(3): 349-359. DOI: 10.1007/s00417-010-1484-9.
25. Stunf Pukl S, Vidović Valentinčič N, Urbančič M, et al. Visual acuity, retinal sensitivity, and macular thickness changes in diabetic patients without diabetic retinopathy after cataract surgery[J/OL]. J Diabetes Res, 2017, 2017: 3459156[2017-01-24]. https://pubmed.ncbi.nlm.nih.gov/28243608/. DOI: 10.1155/2017/3459156.
26. Liu L, Herrinton LJ, Alexeeff S, et al. Visual outcomes after cataract surgery in patients with type 2 diabetes[J]. J Cataract Refract Surg, 2019, 45(4): 404-413. DOI: 10.1016/j.jcrs.2018.11.002.
27. Zhu B, Ma Y, Lin S, et al. Vision-related quality of life and visual outcomes from cataract surgery in patients with vision-threatening diabetic retinopathy: a prospective observational study[J]. Health Qual Life Outcomes, 2017, 15(1): 175. DOI: 10.1186/s12955-017-0751-4.
28. Yonekawa Y, Kim IK. Pseudophakic cystoid macular edema[J]. Curr Opin Ophthalmol, 2012, 23(1): 26-32. DOI: 10.1097/ICU.0b013e32834cd5f8.
29. Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes[J]. Ophthalmology, 2016, 123(2): 316-323. DOI: 10.1016/j.ophtha.2015.10.001.
30. Yang J, Cai L, Sun Z, et al. Risk factors for and diagnosis of pseudophakic cystoid macular edema after cataract surgery in diabetic patients[J]. J Cataract Refract Surg, 2017, 43(2): 207-214. DOI: 10.1016/j.jcrs.2016.11.047.
31. Zaczek A, Olivestedt G, Zetterstrom C. Visual outcome after phacoemulsification and IOL implantation in diabetic patients[J]. Br J Ophthalmol, 1999, 83(9): 1036-1041. DOI: 10.1136/bjo.83.9.1036.
32. Mittra RA, Borrillo JL, Dev S, et al. Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus[J]. Arch Ophthalmol, 2000, 118(7): 912-917.
33. Hong T, Mitchell P, de Loryn T, et al. Development and progression of diabetic retinopathy 12 months after phacoemulsification cataract surgery[J]. Ophthalmology, 2009, 116(8): 1510-1514. DOI: 10.1016/j.ophtha.2009.03.003.
34. Jeng CJ, Hsieh YT, Yang CM, et al. Development of diabetic retinopathy after cataract surgery[J/OL]. PLoS One, 2018, 13(8): e202347[2018-08-22]. https://pubmed.ncbi.nlm.nih.gov/30133506/. DOI: 10.1371/journal.pone.0202347.
35. Brito PN, Rosas VM, Coentrão LM, et al. Evaluation of visual acuity, macular status, and subfoveal choroidal thickness changes after cataract surgery in eyes with diabetic retinopathy[J]. Retina, 2015, 35(2): 294-302. DOI: 10.1097/IAE.0000000000000298.
36. Tang J, Kern TS. Inflammation in diabetic retinopathy[J]. Prog Retin Eye Res, 2011, 30(5): 343-358. DOI: 10.1016/j.preteyeres.2011.05.002.
37. Liu Y, Luo L, He M, et al. Disorders of the blood-aqueous barrier after phacoemulsification in diabetic patients[J]. Eye (Lond), 2004, 18(9): 900-904. DOI: 10.1038/sj.eye.6701349.
38. Grzybowski A, Kanclerz P, Huerva V, et al. Diabetes and phacoemulsification cataract surgery: difficulties, risks and potential complications[J]. J Clin Med, 2019, 8(5): 716. DOI: 10.3390/jcm8050716.
39. Dowler JG, Hykin PG, Hamilton AM. Phacoemulsification versus extracapsular cataract extraction in patients with diabetes[J]. Ophthalmology, 2000, 107(3): 457-462. DOI: 10.1016/s0161-6420(99)00136-0.
40. Jaffe GJ, Burton TC. Progression of nonproliferative diabetic retinopathy following cataract extraction[J]. Arch Ophthalmol, 1988, 106(6): 745-749. DOI: 10.1001/archopht.1988.01060130815029.
41. Squirrell D, Bhola R, Bush J, et al. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes[J]. Br J Ophthalmol, 2002, 86(5): 565-571. DOI: 10.1136/bjo.86.5.565.
42. Diabetic Retinopathy Clinical Research Network Authors/Writing Committee, Baker CW, Almukhtar T, et al. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema[J]. JAMA Ophthalmol, 2013, 131(7): 870-879. DOI: 10.1001/jamaophthalmol.2013.2313.
43. Aiello LM. Perspectives on diabetic retinopathy[J]. Am J Ophthalmol, 2003, 136(1): 122-135. DOI: 10.1016/s0002-9394(03)00219-8.
44. Scott IU, Danis RP, Bressler SB, et al. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema[J]. Retina, 2009, 29(5): 613-617. DOI: 10.1097/IAE.0b013e3181a2c07a.
45. Chung J, Kim MY, Kim HS, et al. Effect of cataract surgery on the progression of diabetic retinopathy[J]. J Cataract Refract Surg, 2002, 28(4): 626-630. DOI: 10.1016/s0886-3350(01)01142-7.
46. Krepler K, Biowski R, Schrey S, et al. Cataract surgery in patients with diabetic retinopathy: visual outcome, progression of diabetic retinopathy, and incidence of diabetic macular oedema[J]. Graefe's Arch Clin Exp Ophthalmol, 2002, 240(9): 735-738. DOI: 10.1007/s00417-002-0530-7.
47. Chen XY, Song WJ, Cai HY, et al. Macular edema after cataract surgery in diabetic eyes evaluated by optical coherence tomography[J]. Int J Ophthalmol, 2016, 9(1): 81-85. DOI: 10.18240/ijo.2016.01.14.
48. Dowler JG, Sehmi KS, Hykin PG, et al. The natural history of macular edema after cataract surgery in diabetes[J]. Ophthalmology, 1999, 106(4): 663-668. DOI: 10.1016/S0161-6420(99)90148-3.
49. Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis[J]. Br J Ophthalmol, 2006, 90(6): 697-701. DOI: 10.1136/bjo.2005.087403.
50. Dong N, Xu B, Wang B, et al. Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery[J/OL]. Biomed Res Int, 2015, 2015: 126984[2015-02-25]. https://pubmed.ncbi.nlm.nih.gov/25811020/. DOI: 10.1155/2015/ 126984.
51. Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution[J]. Clin Ophthalmol, 2009, 3: 199-210. DOI: 10.2147/opth.s4806.
52. Hartnett ME, Tinkham N, Paynter L, et al. Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus[J]. Am J Ophthalmol, 2009, 148(6): 895-901. DOI: 10.1016/j.ajo.2009.07.014.
53. Wielders LHP, Schouten JSAG, Winkens B, et al. Randomized controlled European multicenter trial on the prevention of cystoid macular edema after cataract surgery in diabetics: ESCRS PREMED Study Report 2[J]. J Cataract Refract Surg, 2018, 44(7): 836-847. DOI: 10.1016/j.jcrs.2018.05.015.
54. Fard MA, Yazdanei AA, Malihi M. Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: prospective randomized study[J]. Eur J Ophthalmol, 2011, 21(3): 276-281. DOI: 10.5301/EJO.2010.1405.
55. Udaondo P, Garcia-Pous M, Garcia-Delpech S, et al. Prophylaxis of macular edema with intravitreal ranibizumab in patients with diabetic retinopathy after cataract surgery: a pilot study[J/OL]. J Ophthalmol, 2011, 2011: 159436[2011-06-16]. https://pubmed.ncbi.nlm.nih.gov/21772983/. DOI: 10.1155/2011/159436.
56. Chae JB, Joe SG, Yang SJ, et al. Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy[J]. Retina, 2014, 34(1): 149-156. DOI: 10.1097/IAE.0b013e3182979b9e.
57. Hayashi K, Igarashi C, Hirata A, et al. Changes in diabetic macular oedema after phacoemulsification surgery[J]. Eye (Lond), 2009, 23(2): 389-396. DOI: 10.1038/sj.eye.6703022.
58. Moshfeghi AA, Shapiro H, Lemmon LA, et al. Impact of cataract surgery during treatment with ranibizumab in patients with diabetic macular edema[J]. Ophthalmol Retina, 2018, 2(2): 86-90. DOI: 10.1016/j.oret.2017.05.003.
59. Takamura Y, Kubo E, Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery[J]. Ophthalmology, 2009, 116(6): 1151-1157. DOI: 10.1016/j.ophtha.2009.01.014.
60. Lanzagorta-Aresti A, Palacios-Pozo E, Menezo RJ, et al. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study[J]. Retina, 2009, 29(4): 530-535. DOI: 10.1097/IAE.0b013e31819c6302.
61. Zhao LQ, Cheng JW. A systematic review and meta-analysis of clinical outcomes of intravitreal anti-VEGF agent treatment immediately after cataract surgery for patients with diabetic retinopathy[J/OL]. J Ophthalmol, 2019, 2019: 2648267[2019-04-16]. https://pubmed.ncbi.nlm.nih.gov/31143469/. DOI: 10.1155/2019/2648267.
62. Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10): 1608-1622. DOI: 10.1016/j.ophtha.2018.04.007.

Chinese Journal of Ocular Fundus Diseases

Research progress of anti-vascular endothelial growth factor in cataract surgery for diabetic retinopathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content